By a News Reporter-Staff News Editor at Drug Week -- Research findings on Capsid are discussed in a new report. According to news reporting from Aurora, Colorado, by NewsRx journalists, research stated, "Empty adenovirus serotype 5 (Ad5) capsids devoid of viral genome were developed as a novel delivery system for nanoparticles, proteins, and nucleic acids. Ad5 capsids of 110 nm diameter undergo an increase in particle size to 1637 nm in 1 mM acetic acid at pH 4.0 and then shrink to 60 nm, following pH reversal to 7.4."
The news correspondents obtained a quote from the research from the University of Colorado, "These pH shifts induced reversible changes in capsid zeta potential and secondary structure and irreversible changes in tertiary structure of capsid proteins. Using pH shift dependent changes in capsid size and structure, 20 nm fluorescent nanoparticles, FITC-BSA, and Alexa Fluor ® 488 conjugated siRNA were encapsulated with high efficiency in Ad5 capsids, as confirmed by electron microscopy and/or flow cytometry. HEK cell uptake with capsid delivery system was 7.8-, 7.4-, and 2.9-fold greater for nanoparticles, FITC-BSA, and Alexa-siRNA, respectively, when compared to plain solutes. Physical mixtures of capsids and fluorescent solutes exhibited less capsid associated fluorescence intensity and cell uptake. Further, unlike physical mixture, pH shift assembled Ad5 capsids protected siRNA from RNase degradation. Ad5 capsids before and after pH shift exhibited endolysosomal escape."
According to the news reporters, the research concluded: "Thus, empty Ad5 capsids can encapsulate a variety of solutes based on pH shift assembly, resulting in enhanced cellular delivery."
For more information on this research see: pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. Journal of Controlled Release, 2013;172(1):341-350. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news journalists report that additional information may be obtained by contacting V.R. Rao, University of Colorado, Dept. of Bioengn, Aurora, CO 80045, United States. Additional authors for this research include A.K. Upadhyay and U.B. Kompella (see also Capsid).
Keywords for this news article include: Aurora, Virion, Colorado, Peptides, Amino Acids, Nanoparticle, United States, Nanotechnology, Viral Proteins, Emerging Technologies, Nucleocapsid Proteins, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC